RPGLIFE · NSE
Not in active coverage. Cited reporting has mentioned RPG Life Sciences, the record of those mentions is below. Your interest is logged; coverage expands by demand.
RPG Life Sciences announced that the board of its subsidiary, RPG Active Pharma, approved a scheme of amalgamation of Actis Generics with RPG Active Pharma on September 25, 2026.
RPG Life Sciences spent ₹215 crore on two acquisitions in five weeks to expand its active pharmaceutical ingredients business.
RPG Life Sciences is planning to deploy Rs 500 crore over the next 12 months to strengthen its manufacturing and API capabilities through strategic acquisitions.
RPG Life Sciences is set to launch its GLP-1 product in October.
RPG Active Pharma Ltd, a wholly-owned subsidiary of RPG Life Sciences Ltd, has entered into a Business Transfer Agreement to acquire the API and intermediates business of Raghava Life Sciences Private Ltd for a consideration of up to ₹135 crore.
This page lists where cited reporting has mentioned RPG Life Sciences. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.